Update on conjunctival lymphoma

Kartik Telukuntla, Carol Karp

Research output: Contribution to journalArticle

Abstract

Conjunctival lymphoma is a malignant growth of lymphoid cells on the ocular surface. Clinically, it can present either as a salmon patch or as a follicular form. The etiology of this type of cancer remains unknown, although new research has demonstrated a possible link to infectious agents including Chlamydia psittaci and hepatitis C. When the lymphoma is localized, the current standard of care is external beam radiation, although new therapeutic options include intralesional injections of interferon or rituximab. If systemic, treatment options now include doxycycline, rituximab (Rituxan), and Y-90 ibritumomab tiuxetan (Zevalin). This article explores the new research and treatment options for conjunctival lymphoma.

Original languageEnglish
Pages (from-to)63-67
Number of pages5
JournalTechniques in Ophthalmology
Volume9
Issue number3
DOIs
StatePublished - Sep 1 2011

Fingerprint

Lymphoma
Chlamydophila psittaci
Intralesional Injections
Doxycycline
Salmon
Standard of Care
Hepatitis C
Research
Interferons
Therapeutics
Lymphocytes
Radiation
Growth
Rituximab
Neoplasms
ibritumomab tiuxetan

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Update on conjunctival lymphoma. / Telukuntla, Kartik; Karp, Carol.

In: Techniques in Ophthalmology, Vol. 9, No. 3, 01.09.2011, p. 63-67.

Research output: Contribution to journalArticle

Telukuntla, Kartik ; Karp, Carol. / Update on conjunctival lymphoma. In: Techniques in Ophthalmology. 2011 ; Vol. 9, No. 3. pp. 63-67.
@article{53a21f7b1a10430b9166009e494a67e8,
title = "Update on conjunctival lymphoma",
abstract = "Conjunctival lymphoma is a malignant growth of lymphoid cells on the ocular surface. Clinically, it can present either as a salmon patch or as a follicular form. The etiology of this type of cancer remains unknown, although new research has demonstrated a possible link to infectious agents including Chlamydia psittaci and hepatitis C. When the lymphoma is localized, the current standard of care is external beam radiation, although new therapeutic options include intralesional injections of interferon or rituximab. If systemic, treatment options now include doxycycline, rituximab (Rituxan), and Y-90 ibritumomab tiuxetan (Zevalin). This article explores the new research and treatment options for conjunctival lymphoma.",
author = "Kartik Telukuntla and Carol Karp",
year = "2011",
month = "9",
day = "1",
doi = "10.1097/ITO.0b013e31822fe5ed",
language = "English",
volume = "9",
pages = "63--67",
journal = "Techniques in Ophthalmology",
issn = "1542-1929",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Update on conjunctival lymphoma

AU - Telukuntla, Kartik

AU - Karp, Carol

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Conjunctival lymphoma is a malignant growth of lymphoid cells on the ocular surface. Clinically, it can present either as a salmon patch or as a follicular form. The etiology of this type of cancer remains unknown, although new research has demonstrated a possible link to infectious agents including Chlamydia psittaci and hepatitis C. When the lymphoma is localized, the current standard of care is external beam radiation, although new therapeutic options include intralesional injections of interferon or rituximab. If systemic, treatment options now include doxycycline, rituximab (Rituxan), and Y-90 ibritumomab tiuxetan (Zevalin). This article explores the new research and treatment options for conjunctival lymphoma.

AB - Conjunctival lymphoma is a malignant growth of lymphoid cells on the ocular surface. Clinically, it can present either as a salmon patch or as a follicular form. The etiology of this type of cancer remains unknown, although new research has demonstrated a possible link to infectious agents including Chlamydia psittaci and hepatitis C. When the lymphoma is localized, the current standard of care is external beam radiation, although new therapeutic options include intralesional injections of interferon or rituximab. If systemic, treatment options now include doxycycline, rituximab (Rituxan), and Y-90 ibritumomab tiuxetan (Zevalin). This article explores the new research and treatment options for conjunctival lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=80053044018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053044018&partnerID=8YFLogxK

U2 - 10.1097/ITO.0b013e31822fe5ed

DO - 10.1097/ITO.0b013e31822fe5ed

M3 - Article

VL - 9

SP - 63

EP - 67

JO - Techniques in Ophthalmology

JF - Techniques in Ophthalmology

SN - 1542-1929

IS - 3

ER -